PRINCIPAL DISPLAY PANEL
NDC 0143-9878-01
CEFOXITIN
FOR INJECTION, USP
1 g*/vial
FOR IV USE ONLY
Rx ONLY
* Each vial contains cefoxitin sodium equivalent to 1 g
cefoxitin. The sodium content is 53.8 mg (2.3 mEq).
For the preparation of IV solutions and the
USUAL ADULT DOSAGE: See package insert.
After initial constitution, the solution maintains
satisfactory potency for 6 hours at room temperature
or for 1 week under refrigeration (below 5ºC (41ºF)).
Store dry material between 2º to 25ºC (36º to 77ºF).
Avoid exposure to temperatures above 50ºC (122ºF).
Color changes in powder or solution do not affect
potency.Date/Time _________________ / _________________
NDC 0143-9878-25 Rx ONLY
CEFOXITIN
FOR INJECTION, USP
1 g*/vial
FOR IV USE ONLY 25 x 1 g vials
PRINCIPAL DISPLAY PANEL
NDC 0143-9877-01
CEFOXITIN
FOR INJECTION, USP
2 g*/vial
FOR IV USE ONLY
Rx ONLY
* Each vial contains cefoxitin sodium equivalent to 2 g
cefoxitin. The sodium content is 107.6 mg (4.6 mEq).
For the preparation of IV solutions and the
USUAL ADULT DOSAGE: See package insert.
After initial constitution, the solution maintains
satisfactory potency for 6 hours at room temperature
or for 1 week under refrigeration (below 5ºC (41ºF)).
Store dry material between 2º to 25ºC (36º to 77ºF).
Avoid exposure to temperatures above 50ºC (122ºF).
Color changes in powder or solution do not affect
potency.
Date/Time _________________ / _________________
NDC 0143-9877-25 Rx ONLY
CEFOXITIN
FOR INJECTION, USP
2 g*/vial
FOR IV USE ONLY 25 x 2 g Vials
SERIALIZATION IMAGE
CEFOXITIN cefoxitin injection, powder, for solution |
|
|
|
|
|
|
CEFOXITIN cefoxitin injection, powder, for solution |
|
|
|
|
|
|
Revised: 04/2023 Hikma Pharmaceuticals USA Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/cefoxitin-3/page/5/